0002007919-26-000020
SEC filingInhibrx reported positive interim Phase 2 data for INBRX-106 in first-line HNSCC, showing improved response rates and T-cell activation versus pembrolizumab alone.
Inhibrx announced positive interim Phase 2 data from the HexAgon study evaluating INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab versus pembrolizumab monotherapy in first-line PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent HNSCC. The evaluable population included 53 patients (25 combination, 28 control). The combination arm demonstrated a confirmed objective response rate (cORR) of 44.0% versus 21.4% in the control arm, with three complete responses in the combination arm versus none in the control. Pharmacodynamic data showed up to 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and up to 4-fold increase in activation in the combination arm, supporting the mechanism of action. The safety profile was manageable, with no treatment-related deaths. The company plans to initiate the Phase 3 portion of HexAgon in Q3 2026 and expects PFS data in Q4 2026. Additionally, Inhibrx aims to evaluate INBRX-106 in perioperative NSCLC later this quarter and in front-line metastatic NSCLC beginning in 2027. These results provide early evidence of INBRX-106's potential to enhance checkpoint inhibitor efficacy, representing a significant step for the company's pipeline.